在四家欧洲医院的结核分枝杆菌临床分离株对苯并噻嗪酮均具有一致的敏感性。
Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones.
机构信息
University of Pavia, Department of Genetics and Microbiology, Via Ferrata 1, 27100 Pavia, Italy.
出版信息
Antimicrob Agents Chemother. 2010 Apr;54(4):1616-8. doi: 10.1128/AAC.01676-09. Epub 2010 Jan 19.
Abstract
The new antitubercular drug candidate 2-[2-S-methyl-1,4-dioxa-8-azaspiro[4.5]dec-8-yl]-8-nitro-6-(trifluoromethyl)-4H-1,3-benzothiazin-4-one (BTZ043) targets the DprE1 (Rv3790) subunit of the enzyme decaprenylphosphoryl-beta-d-ribose 2'-epimerase. To monitor the potential development of benzothiazinone (BTZ) resistance, a total of 240 sensitive and multidrug-resistant Mycobacterium tuberculosis clinical isolates from four European hospitals were surveyed for the presence of mutations in the dprE1 gene and for BTZ susceptibility. All 240 strains were susceptible, thus establishing the baseline prior to the introduction of BTZ043 in clinical trials.
摘要
新型抗结核候选药物 2-[2-S-甲基-1,4-二恶烷-8-氮杂螺[4.5]癸-8-基]-8-硝基-6-(三氟甲基)-4H-1,3-苯并噻嗪-4-酮（BTZ043）靶向酶去烯丙基磷酸-β-D-核糖 2'-差向异构酶的 DprE1（Rv3790）亚基。为了监测苯并噻嗪酮（BTZ）耐药性的潜在发展，对来自四家欧洲医院的 240 株敏感和多药耐药结核分枝杆菌临床分离株进行了 dprE1 基因突变检测和 BTZ 敏感性检测。所有 240 株菌株均敏感，从而在 BTZ043 临床试验之前建立了基线。
相似文献
1
Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones.在四家欧洲医院的结核分枝杆菌临床分离株对苯并噻嗪酮均具有一致的敏感性。
Antimicrob Agents Chemother. 2010 Apr;54(4):1616-8. doi: 10.1128/AAC.01676-09. Epub 2010 Jan 19.
2
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.苯并噻嗪酮通过阻断阿拉伯聚糖的合成来杀死结核分枝杆菌。
Science. 2009 May 8;324(5928):801-4. doi: 10.1126/science.1171583. Epub 2009 Mar 19.
3
Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.结核分枝杆菌中DprE1介导的苯并噻嗪酮耐药性的特征分析
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6451-6459. doi: 10.1128/AAC.01523-16. Print 2016 Nov.
4
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.苯并噻嗪酮先导化合物 BTZ043 对结核分枝杆菌的体外联合研究。
Antimicrob Agents Chemother. 2012 Nov;56(11):5790-3. doi: 10.1128/AAC.01476-12. Epub 2012 Aug 27.
5
The 8-Pyrrole-Benzothiazinones Are Noncovalent Inhibitors of DprE1 from Mycobacterium tuberculosis.8-吡咯-苯并噻嗪酮是结核分枝杆菌DprE1的非共价抑制剂。
Antimicrob Agents Chemother. 2015 Aug;59(8):4446-52. doi: 10.1128/AAC.00778-15. Epub 2015 May 18.
6
Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target.结核分枝杆菌的脱磷酸-β-D-核糖基 2′-差向异构酶是一种神奇的药物靶点。
Curr Med Chem. 2010;17(27):3099-108. doi: 10.2174/092986710791959693.
7
Mutations in Confer Low-Level Resistance to Benzothiazinone DprE1 Inhibitors in Mycobacterium tuberculosis.突变使结核分枝杆菌中的 DprE1 苯并噻唑酮抑制剂产生低水平耐药性。
Antimicrob Agents Chemother. 2022 Sep 20;66(9):e0090422. doi: 10.1128/aac.00904-22. Epub 2022 Aug 3.
8
Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis.苯并噻嗪酮类化合物：可共价修饰分枝杆菌的二磷酸核酮糖异构酶 DprE1 的前药。
J Am Chem Soc. 2010 Oct 6;132(39):13663-5. doi: 10.1021/ja106357w.
9
Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents.设计、合成及评价 DprE1 的共价抑制剂作为抗结核药物。
Eur J Med Chem. 2020 Dec 15;208:112773. doi: 10.1016/j.ejmech.2020.112773. Epub 2020 Aug 30.
10
Mutations associated with in vitro resistance to bedaquiline in Mycobacterium tuberculosis isolates in Australia.澳大利亚结核分枝杆菌分离株中与体外对贝达喹啉耐药相关的突变
Tuberculosis (Edinb). 2018 Jul;111:31-34. doi: 10.1016/j.tube.2018.04.007. Epub 2018 Apr 25.
引用本文的文献
1
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043.抗结核药物BTZ-043的群体药代动力学及暴露-反应关系
J Antimicrob Chemother. 2025 May 2;80(5):1315-1323. doi: 10.1093/jac/dkaf076.
2
The clinical-stage drug BTZ-043 accumulates in murine tuberculosis lesions and efficiently acts against Mycobacterium tuberculosis.临床阶段药物BTZ-043在小鼠结核病灶中蓄积，并能有效对抗结核分枝杆菌。
Nat Commun. 2025 Jan 18;16(1):826. doi: 10.1038/s41467-025-56146-9.
3
DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid.DprE2 是抗结核硝基咪唑化合物丙硫异烟胺和德拉马尼的分子靶标。
Nat Commun. 2023 Jun 28;14(1):3828. doi: 10.1038/s41467-023-39300-z.
4
Pharmacokinetics and Efficacy of the Benzothiazinone BTZ-043 against Tuberculous Mycobacteria inside Granulomas in the Guinea Pig Model.苯并噻嗪酮 BTZ-043 对豚鼠肉芽肿内分枝杆菌的药代动力学和疗效。
Antimicrob Agents Chemother. 2023 Apr 18;67(4):e0143822. doi: 10.1128/aac.01438-22. Epub 2023 Mar 28.
5
Assay development and inhibition of the -DprE2 essential reductase from .-DprE2 必需还原酶的测定开发及抑制作用研究。
Microbiology (Reading). 2023 Jan;169(1). doi: 10.1099/mic.0.001288.
6
Optimized LC-MS/MS quantification of tuberculosis drug candidate macozinone (PBTZ169), its dearomatized Meisenheimer Complex and other metabolites, in human plasma and urine.优化的 LC-MS/MS 定量分析结核药物候选物马佐酮（PBTZ169）、其去芳构化的 Meisenheimer 复合物和其他代谢物在人血浆和尿液中的浓度。
J Chromatogr B Analyt Technol Biomed Life Sci. 2023 Jan 15;1215:123555. doi: 10.1016/j.jchromb.2022.123555. Epub 2022 Dec 9.
7
Antituberculosis Macozinone Extended-Release Tablets To Enhance Bioavailability: a Pilot Pharmacokinetic Study in Beagle Dogs.抗结核药马卡嗪酮缓释片提高生物利用度：在比格犬中的初步药代动力学研究。
Microbiol Spectr. 2023 Feb 14;11(1):e0232722. doi: 10.1128/spectrum.02327-22. Epub 2022 Dec 12.
8
Recent Advances of DprE1 Inhibitors against : Computational Analysis of Physicochemical and ADMET Properties.DprE1抑制剂的最新进展：理化性质和药物代谢动力学、药物毒性及药物效应动力学性质的计算分析
ACS Omega. 2022 Nov 3;7(45):40659-40681. doi: 10.1021/acsomega.2c05307. eCollection 2022 Nov 15.
9
Repurposing the Pathogen Box compounds for identification of potent anti-malarials against blood stages of Plasmodium falciparum with PfUCHL3 inhibitory activity.利用病原体箱化合物重新开发针对恶性疟原虫血期具有 PfUCHL3 抑制活性的强效抗疟药物。
Sci Rep. 2022 Jan 18;12(1):918. doi: 10.1038/s41598-021-04619-4.
10
Discovery of novel DprE1 inhibitors via computational bioactivity fingerprints and structure-based virtual screening.通过计算生物活性指纹和基于结构的虚拟筛选发现新型 DprE1 抑制剂。
Acta Pharmacol Sin. 2022 Jun;43(6):1605-1615. doi: 10.1038/s41401-021-00779-1. Epub 2021 Oct 19.
本文引用的文献
1
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors.高通量筛选鉴定出脱磷酸核糖基焦磷酸 2'-差向异构酶为细胞内抗分枝杆菌抑制剂的靶标。
PLoS Pathog. 2009 Oct;5(10):e1000645. doi: 10.1371/journal.ppat.1000645. Epub 2009 Oct 30.
2
Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community.耐多药和广泛耐药结核病：对全球艾滋病群体的影响
Curr Opin Infect Dis. 2009 Feb;22(1):11-7. doi: 10.1097/QCO.0b013e3283210020.
3
Mycobacterium tuberculosis: drug resistance and future perspectives.结核分枝杆菌：耐药性与未来展望。
Future Microbiol. 2009 Jun;4(5):597-614. doi: 10.2217/fmb.09.20.
4
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis.苯并噻嗪酮通过阻断阿拉伯聚糖的合成来杀死结核分枝杆菌。
Science. 2009 May 8;324(5928):801-4. doi: 10.1126/science.1171583. Epub 2009 Mar 19.
5
Biosynthesis of D-arabinose in mycobacteria - a novel bacterial pathway with implications for antimycobacterial therapy.分枝杆菌中D-阿拉伯糖的生物合成——一种对抗分枝杆菌治疗有影响的新型细菌途径。
FEBS J. 2008 Jun;275(11):2691-711. doi: 10.1111/j.1742-4658.2008.06395.x. Epub 2008 Apr 15.
6
The biological cost of mutational antibiotic resistance: any practical conclusions?突变性抗生素耐药性的生物学代价：有哪些实际结论？
Curr Opin Microbiol. 2006 Oct;9(5):461-5. doi: 10.1016/j.mib.2006.07.002. Epub 2006 Aug 4.
7
Genes required for mycobacterial growth defined by high density mutagenesis.通过高密度诱变确定的分枝杆菌生长所需基因。
Mol Microbiol. 2003 Apr;48(1):77-84. doi: 10.1046/j.1365-2958.2003.03425.x.
Zotero 插件